Phathom initiates Phase 3 registrational study of VOQUEZNA for non-erosive GERD

Phathom Pharmaceuticals announced initiation of a registrational Phase 3 study of VOQUEZNA (vonoprazan) for as-needed treatment of non-erosive GERD.